This review article is concerned with current knowledge on the role of galectin-3 in metabolic disorders and the mechanism by which this lectin eventually modulates excess fat mass, adipose tissue and systemic inflammation, and the associated impairment in glucose regulation, with a view to highlighting the unresolved issues that deserve further research. The gene discussed is LGALS3; the disease is metabolic disease.